Bicara Therapeutics (BCAX)

Executive Summary

Bicara Therapeutics is a clinical-stage biotechnology company pioneering bifunctional biologics that simultaneously target tumors and modulate the immune microenvironment. Its lead candidate, ficerafusp alfa, is a first-in-class bispecific antibody designed to block EGFR while engaging CD47 to enhance anti-tumor immunity. The company is advancing ficerafusp alfa in combination with pembrolizumab for head and neck squamous cell carcinoma (HNSCC), with a Phase 2/3 trial (NCT06788990) in metastatic/recurrent HNSCC that began enrolling in early 2025. A separate Phase 2 trial (NCT07465276) in HNSCC is set to start in April 2026. Bicara's dual-mechanism approach aims to overcome resistance to checkpoint inhibitors and improve outcomes in solid tumors. With a strong scientific rationale and a large addressable market in HNSCC, the company represents a compelling investment opportunity in the immuno-oncology space.

Upcoming Catalysts (preview)

• H2 2027Initial data from Phase 2 trial of ficerafusp alfa + pembrolizumab in HNSCC60% success
• 2028Interim analysis from Phase 2/3 trial in metastatic HNSCC55% success
• 2026Potential FDA regulatory designation (e.g., Fast Track or Breakthrough Therapy)40% success